Literature DB >> 26687234

Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Louise M Collins1, Giorgia Dal Bo1,2, Mariangela Calcagno2, Jimena Monzón-Sandoval3,4, Aideen M Sullivan1, Humberto Gutierrez3, Michele Morari5, Gerard W O'Keeffe6.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) is an opioid-like neuropeptide that binds and signals through a G-protein-coupled receptor called the N/OFQ peptide (NOP) receptor. N/OFQ and the NOP receptor are expressed in the midbrain and have been implicated in the pathogenesis of Parkinson's disease (PD). Genetic removal of the N/OFQ precursor partially protects midbrain dopaminergic neurons from 1-methyl-4-phenylpyridine-induced toxicity, suggesting that endogenous N/OFQ may be detrimental to dopaminergic neurons. However, whether N/OFQ directly affects the survival and growth of dopaminergic neurons is unknown. Here, we show that N/OFQ has a detrimental effect on the survival of dopaminergic neurons and the growth of their axons in primary cultures of the E14 rat ventral mesencephalon. N/OFQ potentiates the effects of the neurotoxins 6-hydroxydopamine and 1-methyl-4-phenylpyridinium through p38-MAPK signalling. We also show that like α-synuclein, there is a significant reduction in N/OFQ messenger RNA (mRNA) expression in the midbrain of patients with Parkinson's disease. These results demonstrate for the first time that N/OFQ is detrimental to the survival and growth of dopaminergic neurons and that its expression is altered in the midbrain of patients with Parkinson's disease.

Entities:  

Keywords:  Axon; Dopaminergic; Growth; Human; Neuron; Nociceptin/orphanin FQ; Parkinson’s disease; Survival; p38-MAPK

Mesh:

Substances:

Year:  2015        PMID: 26687234     DOI: 10.1007/s12035-015-9611-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  69 in total

1.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

Review 2.  Progress in Parkinson's disease-where do we stand?

Authors:  André Toulouse; Aideen M Sullivan
Journal:  Prog Neurobiol       Date:  2008-06-05       Impact factor: 11.685

3.  Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat.

Authors:  C R Neal; A Mansour; R Reinscheid; H P Nothacker; O Civelli; S J Watson
Journal:  J Comp Neurol       Date:  1999-04-19       Impact factor: 3.215

4.  BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Cell Neurosci       Date:  2013-07-03       Impact factor: 4.314

5.  Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro.

Authors:  Gerard W O'Keeffe; Peter Dockery; Aideen M Sullivan
Journal:  J Neurocytol       Date:  2004-09

6.  Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat.

Authors:  M Marti; R Guerrini; L Beani; C Bianchi; M Morari
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

7.  Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.

Authors:  Mattia Volta; Omar S Mabrouk; Simone Bido; Matteo Marti; Michele Morari
Journal:  J Neurochem       Date:  2010-11-11       Impact factor: 5.372

8.  In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Anna Rizzi; Barbara Spagnolo; Richard D Wainford; Carmela Fischetti; Remo Guerrini; Giuliano Marzola; Anna Baldisserotto; Severo Salvadori; Domenico Regoli; Daniel R Kapusta; Girolamo Calo
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

9.  Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat.

Authors:  D Stanic; D I Finkelstein; D W Bourke; J Drago; M K Horne
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

10.  Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization.

Authors:  Akihiko Ozawa; Gloria Brunori; Daniela Mercatelli; Jinhua Wu; Andrea Cippitelli; Bende Zou; Xinmin Simon Xie; Melissa Williams; Nurulain T Zaveri; Sarah Low; Grégory Scherrer; Brigitte L Kieffer; Lawrence Toll
Journal:  J Neurosci       Date:  2015-08-19       Impact factor: 6.167

View more
  4 in total

Review 1.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

2.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

3.  Parkinson's disease: no NOP, new hope.

Authors:  Ludovico Arcuri; Daniela Mercatelli; Michele Morari
Journal:  Oncotarget       Date:  2017-02-07

4.  Comparison of Rat Primary Midbrain Neurons Cultured in DMEM/F12 and Neurobasal Mediums.

Authors:  Neda Valian; Mansooreh Heravi; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Basic Clin Neurosci       Date:  2021-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.